- Home
- TIL vs CATX Comparison
TIL vs CATX Comparison
Compare TIL & CATX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TIL
- CATX
- Stock Information
- Founded
- TIL 2018
- CATX 1983
- Country
- TIL United States
- CATX United States
- Employees
- TIL N/A
- CATX N/A
- Industry
- TIL Biotechnology: Pharmaceutical Preparations
- CATX Medical/Dental Instruments
- Sector
- TIL Health Care
- CATX Health Care
- Exchange
- TIL Nasdaq
- CATX Nasdaq
- Market Cap
- TIL 171.7M
- CATX 182.9M
- IPO Year
- TIL 2021
- CATX N/A
- Fundamental
- Price
- TIL $13.23
- CATX $2.34
- Analyst Decision
- TIL Buy
- CATX Strong Buy
- Analyst Count
- TIL 5
- CATX 10
- Target Price
- TIL $114.00
- CATX $13.89
- AVG Volume (30 Days)
- TIL 180.4K
- CATX 633.3K
- Earning Date
- TIL 05-20-2025
- CATX 05-12-2025
- Dividend Yield
- TIL N/A
- CATX N/A
- EPS Growth
- TIL N/A
- CATX N/A
- EPS
- TIL N/A
- CATX N/A
- Revenue
- TIL N/A
- CATX $1,454,000.00
- Revenue This Year
- TIL N/A
- CATX N/A
- Revenue Next Year
- TIL N/A
- CATX N/A
- P/E Ratio
- TIL N/A
- CATX N/A
- Revenue Growth
- TIL N/A
- CATX 1.40
- 52 Week Low
- TIL $9.62
- CATX $1.60
- 52 Week High
- TIL $92.00
- CATX $19.10
- Technical
- Relative Strength Index (RSI)
- TIL 44.22
- CATX 51.17
- Support Level
- TIL $11.97
- CATX $2.18
- Resistance Level
- TIL $14.67
- CATX $2.65
- Average True Range (ATR)
- TIL 2.05
- CATX 0.16
- MACD
- TIL -0.04
- CATX 0.02
- Stochastic Oscillator
- TIL 17.87
- CATX 56.25
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize FRα, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.